Episealer® surgery scheduled in France

Episurf Medical (Nasdaq: EPIS B) today announces that a surgery with the Episealer® implant technology has been scheduled to take place in France in the coming weeks. The surgery will be an ankle surgery with the new Episealer® Talus implant. 
“We have work to do in the French market, but it is nice to see, already at this stage, that surgeons are interested in our technology, in this for us new country,” says Pål Ryfors, CEO Episurf Medical. 

 
For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

Tags: